

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

### Drug Information

Pharmacy billing (NDC: \_\_\_\_\_) Start Date (or date of next dose): \_\_\_\_\_

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_

### Billing Provider Information

Pharmacy NPI: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_

Pharmacy Phone: \_\_\_\_\_ Pharmacy Fax: \_\_\_\_\_

### Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

### Criteria

#### For Initial Authorization

##### 1. Please indicate the diagnosis and information:

**Non-Small Cell Lung Cancer (NSCLC)**

A. Is diagnosis recurrent, advanced, or metastatic NSCLC? Yes \_\_\_ No \_\_\_

B. Is tumor rearranged during transfection (RET) fusion positive? Yes \_\_\_ No \_\_\_

C. Will pralsetinib be used as a single agent? Yes \_\_\_ No \_\_\_

**Thyroid Cancer**

A. Is disease advanced or metastatic? Yes \_\_\_ No \_\_\_

B. Is diagnosis RET fusion-positive thyroid cancer? Yes \_\_\_ No \_\_\_

i. If yes, does member require systemic therapy? Yes \_\_\_ No \_\_\_

ii. Is radioactive iodine appropriate for this member? Yes \_\_\_ No \_\_\_

a. If appropriate, is member refractory to radioactive iodine? Yes \_\_\_ No \_\_\_

C. Will pralsetinib be used as a single agent? Yes \_\_\_ No \_\_\_

**If diagnosis is not listed above, please indicate diagnosis:** \_\_\_\_\_

Additional Information: \_\_\_\_\_

#### For Continued Authorization:

1. Date of last dose: \_\_\_\_\_

2. Does member have any evidence of progressive disease while on pralsetinib? Yes \_\_\_ No \_\_\_

3. Has the member experienced adverse drug reactions related to pralsetinib therapy?

Yes \_\_\_ No \_\_\_

If yes, please specify adverse reactions: \_\_\_\_\_

Additional Information: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.**

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy  
Pharmacy Management Consultants  
Product Based Prior Authorization Unit

Fax: 1-800-224-4014  
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.